$254 Million is the total value of Iguana Healthcare Management, LLC's 71 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 60.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RARE | Sell | ULTRAGENYX PHARMACEUTICAL IN | $10,594,000 | -48.3% | 110,000 | -45.0% | 4.17% | -35.5% |
| CELG | Sell | CELGENE CORP | $9,735,000 | -43.9% | 90,000 | -40.0% | 3.83% | -30.1% |
| ESRX | Sell | EXPRESS SCRIPTS HLDG CO | $6,072,000 | -31.7% | 75,000 | -25.0% | 2.39% | -14.9% |
| MDT | Sell | MEDTRONIC PLC | $5,021,000 | -32.2% | 75,000 | -25.0% | 1.98% | -15.5% |
| GWPH | Sell | GW PHARMACEUTICALS PLCads | $3,655,000 | -33.9% | 40,000 | -11.1% | 1.44% | -17.6% |
| XLRN | Sell | ACCELERON PHARMA INC | $2,739,000 | -42.3% | 110,000 | -26.7% | 1.08% | -28.1% |
| IPXL | Sell | IMPAX LABORATORIES INC | $2,641,000 | -54.0% | 75,000 | -40.0% | 1.04% | -42.6% |
| AXDX | Sell | ACCELERATE DIAGNOSTICS INC | $2,427,000 | -65.2% | 150,000 | -44.4% | 0.96% | -56.6% |
| SUPN | Sell | SUPERNUS PHARMACEUTICALS INC | $1,894,000 | -57.9% | 135,000 | -49.1% | 0.74% | -47.5% |
| ELGX | Sell | ENDOLOGIX INC | $1,839,000 | -40.1% | 150,000 | -25.0% | 0.72% | -25.3% |
| DERM | Sell | DERMIRA INC | $1,751,000 | +24.7% | 75,000 | -6.2% | 0.69% | +55.5% |
| AGTC | Sell | APPLIED GENETIC TECHNOL CORP | $1,643,000 | -28.6% | 125,000 | -16.7% | 0.65% | -11.0% |
| ASMB | Sell | ASSEMBLY BIOSCIENCES INC | $1,434,000 | -57.5% | 150,000 | -14.3% | 0.56% | -46.9% |
| ESPR | Sell | ESPERION THERAPEUTICS INC NE | $1,180,000 | -90.4% | 50,000 | -66.7% | 0.46% | -88.0% |
| RXDX | Sell | IGNYTA INC | $1,098,000 | -51.5% | 125,000 | -16.7% | 0.43% | -39.5% |
| IMDZ | Sell | IMMUNE DESIGN CORP | $915,000 | -70.5% | 75,000 | -50.0% | 0.36% | -63.2% |
| Exit | MEI PHARMA INCcall | $0 | – | -150,000 | -100.0% | -0.08% | – | |
| Exit | ZIOPHARM ONCOLOGY INCput | $0 | – | -25,000 | -100.0% | -0.10% | – | |
| Exit | IMMUNOMEDICS INCcall | $0 | – | -75,000 | -100.0% | -0.10% | – | |
| Exit | FLAMEL TECHNOLOGIES SAcall | $0 | – | -25,000 | -100.0% | -0.17% | – | |
| Exit | NOVADAQ TECHNOLOGIES INCcall | $0 | – | -50,000 | -100.0% | -0.19% | – | |
| ETRM | Exit | ENTEROMEDICS INC | $0 | – | -1,075,000 | -100.0% | -0.21% | – |
| CSLT | Exit | CASTLIGHT HEALTH INCcl b | $0 | – | -120,000 | -100.0% | -0.31% | – |
| Exit | SPARK THERAPEUTICS INCcall | $0 | – | -17,500 | -100.0% | -0.33% | – | |
| AFMD | Exit | AFFIMED N V | $0 | – | -100,000 | -100.0% | -0.42% | – |
| KITE | Exit | KITE PHARMA INC | $0 | – | -25,000 | -100.0% | -0.48% | – |
| PACB | Exit | PACIFIC BIOSCIENCES CALIF IN | $0 | – | -275,000 | -100.0% | -0.50% | – |
| CLDX | Exit | CELLDEX THERAPEUTICS INC NEW | $0 | – | -75,000 | -100.0% | -0.60% | – |
| TTPH | Exit | TETRAPHASE PHARMACEUTICALS I | $0 | – | -50,000 | -100.0% | -0.75% | – |
| Exit | HEALTH NET INCcall | $0 | – | -40,000 | -100.0% | -0.81% | – | |
| DBVT | Exit | DBV TECHNOLOGIES S Asponsored adr | $0 | – | -90,000 | -100.0% | -0.84% | – |
| Exit | AGIOS PHARMACEUTICALS INCput | $0 | – | -25,000 | -100.0% | -0.88% | – | |
| ISIS | Exit | ISIS PHARMACEUTICALS INC | $0 | – | -50,000 | -100.0% | -0.91% | – |
| PETX | Exit | ARATANA THERAPEUTICS INC | $0 | – | -200,000 | -100.0% | -0.95% | – |
| IPCM | Exit | IPC HEALTHCARE INC | $0 | – | -75,000 | -100.0% | -1.31% | – |
| Exit | ABBOTT LABScall | $0 | – | -100,000 | -100.0% | -1.55% | – | |
| Exit | AETNA INC NEWcall | $0 | – | -50,000 | -100.0% | -2.01% | – | |
| STJ | Exit | ST JUDE MED INC | $0 | – | -100,000 | -100.0% | -2.30% | – |
| Exit | SELECT SECTOR SPDR TRput | $0 | – | -200,000 | -100.0% | -4.69% | – | |
| Exit | SPDR S&P 500 ETF TRput | $0 | – | -100,000 | -100.0% | -6.49% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC | 17 | Q1 2018 | 7.5% |
| ULTRAGENYX PHARMACEUTICAL IN | 17 | Q1 2018 | 6.7% |
| MERCK & CO INC NEW | 16 | Q1 2018 | 5.4% |
| CELGENE CORP | 15 | Q4 2017 | 7.9% |
| AERIE PHARMACEUTICALS INC | 15 | Q4 2017 | 3.3% |
| GILEAD SCIENCES INC | 14 | Q1 2017 | 6.7% |
| ESPERION THERAPEUTICS INC NE | 14 | Q1 2018 | 7.8% |
| SUPERNUS PHARMACEUTICALS INC | 14 | Q4 2017 | 2.8% |
| DERMIRA INC | 14 | Q1 2018 | 2.7% |
| AMGEN INC | 13 | Q1 2017 | 6.5% |
View Iguana Healthcare Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-16 |
| 13F-HR | 2017-11-14 |
| 13F-HR | 2017-08-14 |
| 13F-HR | 2017-05-15 |
| 13F-HR | 2017-02-14 |
| 13F-HR/A | 2016-11-17 |
| 13F-HR | 2016-11-14 |
| 13F-HR/A | 2016-11-04 |
View Iguana Healthcare Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.